MedinCell Company Description

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.

The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation.

In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1.

It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.

MedinCell S.A.

Country	France
Founded	2003
Industry	Biotechnology
Sector	Healthcare
Employees	141
CEO	Christophe Douat

Contact Details

Address: 3, rue des Frères Lumière Jacou, 34830 France
Phone	33 4 67 02 13 67
Website	medincell.com

Stock Details

Ticker Symbol	MEDCL
Exchange	Euronext Paris
Fiscal Year	April - March
Reporting Currency	EUR
ISIN Number	FR0004065605
SIC Code	2834

Key Executives

Name	Position
Christophe Douat	Chief Executive Officer and Director
Franck Pouzache	Chief People Officer
Stephane Postic	Chief Financial Officer
Philippe Moyen	Chief Operating Officer
Julie Alimi	General Counsel and Chief Corporate Development Officer
David Heuze	Head of Corporate and Financial Communications and ESG
Adolfo Lopez-Noriega	Head of Research and Development
Sebastien Enault	Chief Business Officer
Quiterie De Beauregard	Head of Global Health Development
Dr. Richard Malamut M.D.	Chief Medical Officer